$136.01
-8.42-5.83%
Ult. Agg.: Nov 2, 5:35 PM
Axsome Therapeutics (AXSM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Axsome Therapeutics (AXSM) ha pubblicato l'ultima guidance il gennaio 4, 2024 per fiscal year 2023. La società ha previsto un fatturato pari a $204M - $204M per il periodo.
Rispetto alle previsioni precedenti, Axsome Therapeutics {{epsDirection}} ha modificato le sue previsioni di fatturato da un intervallo precedente di {{epsPriorRange}}.
Axsome Therapeutics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Axsome Therapeutics. 2
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.64 | $-0.87 | $-0.83 | $-0.72 |
| Actual | $-0.25 | $-0.99 | $-1.26 | $-0.56 |
| Surprise | +60.9% | -13.8% | -51.8% | +22.2% |
| Revenue | ||||
| Estimate | $248.6M | $222.3M | $190.3M | $193.2M |
| Actual | $259.7M | $218.4M | $191.2M | $196.0M |
| Surprise | +4.45% | -1.77% | +0.48% | +1.47% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.16 | $-0.29 | $0.24 |
| Revenue | |||
| Consensus | $290.1M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $-0.25 | $-0.64 | 60.9 % |
| Q2 | Aug 10, 2026 | $-0.99 | $-0.87 | -13.8 % |
| Q1 | May 4, 2026 | $-1.26 | $-0.83 | -51.8 % |
| Q4 | Feb 23, 2026 | $-0.56 | $-0.72 | 22.2 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $259.69M | $248.64M | 4.45 % |
| Q2 | Aug 10, 2026 | $218.40M | $222.33M | -1.77 % |
| Q1 | May 4, 2026 | $191.20M | $190.28M | 0.48 % |
| Q4 | Feb 23, 2026 | $196.00M | $193.16M | 1.47 % |